产品名称：Bersanlimab
产品别称：BI-505
靶点：ICAM1[Homo sapiens]
抗体亚型：IgG1 - lambda2
来源：CHO cells
体外实验：Bersanlimab（1 ng/mL-1000 μg/mL）剂量依赖性地诱导表达 ICAM-1 的 Ramos、Raji 和 Daudi 淋巴瘤细胞的程序性细胞死亡[1]。
体内实验：在弥散性多发性骨髓瘤实验模型中，Bersanlimab显著提高了小鼠的生存期，延缓了疾病发作[1]。
| Animal Model | whole-body irradiated mice injected with RPMI-8226 cells |
| Dosage | 2mg /kg |
| Result | Bersanlimab significantly enhanced survival and delayed disease |
参考文献：1.Veitonmäki N, Hansson M, Zhan F, et al. A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. 2013;23(4):502-515. doi:10.1016/j.ccr.2013.02.026
仅供科研使用
